References
- Neuwelt E, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T et al. Strategies to advance translational research into brain barriers. Lancet Neurol 2008;7:84–96.
- Müller RH, Maassen S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996;4:161–170.
- Chen D, Lee KH. Biodistribution of calcitonin encapsulated in liposomes in mice with particular reference to the central nervous system. Biochim Biophys Acta 1993;1158:244–250.
- Wang JX, Sun X, Zhang ZR. Enhanced brain targeting by synthesis of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm 2002;54:285–290.
- Fazil M, Shadab, Baboota S, Sahni JK, Ali J. Nanotherapeutics for Alzheimer’s disease (AD): Past, present and future. J Drug Target 2012;20:97–113.
- Moghimi SM, Porter CJ, Muir IS, Illum L, Davis SS. Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem Biophys Res Commun 1991;177:861–866.
- Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer’s disease. J Control Release 2005;108:193–214.
- Oyewumi MO, Yokel RA, Jay M, Coakley T, Mumper RJ. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J Control Release 2004;95:613–626.
- Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283–318.
- Chen Y, Liu L. Modern methods for delivery of drugs across the blood–brain barrier. Adv Drug Delivery Rev.
- Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2005;2:108–119.
- Károly M, Vámos J, Nemes A, Rácz A, Noszál B. Lipophilicity of vinpocetine and related compounds characterized by reversed-phase thin-layer chromatography. J Chromatogr A 2003;996:195–203.
- Ribeiro L, Loftsson T, Ferreira D, Veiga F. Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether beta-cyclodextrin binary and ternary complexes. Chem Pharm Bull 2003;51:914–922.
- Bönöczk P, Gulyás B, Adam-Vizi V, Nemes A, Kárpáti E, Kiss B et al. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull 2000;53:245–254.
- Miskolczi P, Kozma K, Polgár M, Vereczkey L. Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur J Drug Metab Pharmacokinet 1990;15:1–5.
- Sanna V, Caria G, Mariani A. Effect of lipid nanoparticles containing fatty alcohols having different chain length on the ex vivo skin permeability of Econazole nitrate. Powder Tech 2010;201:32–36.
- Aji Alex MR, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci 2011;42:11–18.
- Kheradmandnia S, Vasheghani-Farahani E, Nosrati M, Atyabi F. Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomedicine 2010;6:753–759.
- Xie S, Zhu L, Dong Z, Wang X, Wang Y, Li X et al. Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids Surf B Biointerfaces 2011;83:382–387.
- Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C et al. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm 2008;357:295–304.
- Kumar VV, Chandrasekar D, Ramakrishna S, Kishan V, Rao YM, Diwan PV. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm 2007;335:167–175.
- Ghadiri M, Fatemi S, Vatanara A, Doroud D, Najafabadi AR, Darabi M et al. Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size. Int J Pharm 2012;424:128–137.
- Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 2009;133:238–244.
- Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J Control Release 2006;114:53–59.
- Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–177.
- Lv Q, Yu A, Xi Y, Li H, Song Z, Cui J et al. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm 2009;372:191–198.
- Westesen K, Siekmann B, Koch MHJ. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm 1993;93:189–199.
- Han F, Li S, Yin R, Liu H, Xu L. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: Nanostructured lipid carriers. Colloids Surf A Physicochem Eng Asp 2008;315:210–216.
- Tan SW, Billa N, Roberts CR, Burley JC. Surfactant effects on the physical characteristics of Amphotericin B-containing nanostructured lipid carriers. Colloids Surf A Physicochem Eng Asp 2010;372:73–79.
- Riddick TM. Zeta-meter manual. New York, 1986.
- Sinha VR, Srivastava S, Goel H, Jindal V. Solid lipid nanoparticles (SLN’S) – trends and implications in drug targeting. Int J Adv Pharm Sci 2010;1:212–218.
- Siekmann B, Westesen K. Submicron-sized parenteral carrier systems based on solid lipids. Pharm Pharmacol Lett 1992;1:123–126.
- Lu B, Xiong SB, Yang H, Yin XD, Chao RB. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur J Pharm Sci 2006;28:86–95.
- Seeballuck F, Lawless E, Ashford MB, O’Driscoll CM. Stimulation of triglyceride-rich lipoprotein secretion by polysorbate 80: in vitro and in vivo correlation using Caco-2 cells and a cannulated rat intestinal lymphatic model. Pharm Res 2004;21:2320–2326.
- zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery–drug release and release mechanism. Eur J Pharm Biopharm 1998;45:149–155.
- Severino P, Pinho SC, Souto EB, Santana MH. Polymorphism, crystallinity and hydrophilic-lipophilic balance of stearic acid and stearic acid-capric/caprylic triglyceride matrices for production of stable nanoparticles. Colloids Surf B Biointerfaces 2011;86:125–130.
- Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999;59:299–307.
- Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257–1272.
- Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 2011;85:262–269.
- Zeta potential theory. Malvern Instruments Ltd, 2008.
- Company M. http://www.malvern.com/LabEng/technology/dynamic_light_scattering/dynamic_light_scattering.htm.
- Brar SK, Verma M. Measurement of nanoparticles by light-scattering techniques. TrAC Trends Analyt Chem 2011;30:4–17.